Advertisement

 

 

OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.

OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.
Author Information (click to view)

Domínguez C, Pozo-Rosich P, Torres-Ferrús M, Hernández-Beltrán N, Jurado-Cobo C, González-Oria C, Santos S, Monzón MJ, Latorre G, Álvaro LC, Gago A, Gallego M, Medrano V, Huerta M, García-Alhama J, Belvís R, Leira Y, Leira R,


Domínguez C, Pozo-Rosich P, Torres-Ferrús M, Hernández-Beltrán N, Jurado-Cobo C, González-Oria C, Santos S, Monzón MJ, Latorre G, Álvaro LC, Gago A, Gallego M, Medrano V, Huerta M, García-Alhama J, Belvís R, Leira Y, Leira R, (click to view)

Domínguez C, Pozo-Rosich P, Torres-Ferrús M, Hernández-Beltrán N, Jurado-Cobo C, González-Oria C, Santos S, Monzón MJ, Latorre G, Álvaro LC, Gago A, Gallego M, Medrano V, Huerta M, García-Alhama J, Belvís R, Leira Y, Leira R,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

European journal of neurology 2017 11 24() doi 10.1111/ene.13523
Abstract
BACKGROUND
OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of chronic migraine in adults. The aim of this study was to assess the effectiveness of OnabotulinumtoxinA in chronic migraine after 1 year of treatment in the real-life setting and to identify clinical predictors of outcome.

METHODS
We designed a prospective multicentre study performed in 13 Hospitals in Spain. Patients underwent a complete medical history and examination. They received treatment with OnabotulinumtoxinA every 12 weeks over a year. Data about outcome, adverse events, abortive medication use, emergency room use and disability were collected at month 3 and 12.

RESULTS
Seven hundred and twenty-five subjects completed the study. At 12 months, 79.3% showed >50% reduction in number of headaches per month and 94.9% reported no adverse events. Unilaterality of pain, fewer days of disability per month and milder headache at baseline were correlated with good outcome. Duration of disease <12 months increased the chances of response to treatment with OnabotulinumtoxinA (OR 1.470; CI 95% 1.1.23-2.174, p=0.045). CONCLUSIONS
This study confirms effectiveness of treatment with OnabotulinumtoxinA after 1 year of treatment. Chances of having a good outcome may be increased by starting treatment in the first 12 months after chronic migraine diagnosis. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

20 − three =

[ HIDE/SHOW ]